Placebo | AZD7594 | |||
---|---|---|---|---|
(n = 52) | 58 μg (n = 34) | 250 μg (n = 34) | 800 μg (n = 34) | |
Demographics | ||||
Age, years Mean (SD) | 51 (12) | 51 (12) | 50 (12) | 51 (12) |
Male n (%) | 44 (84.6%) | 26 (76.5%) | 30 (88.2%) | 28 (82.3%) |
White n (%) | 51 (98.1%) | 33 (97.1%) | 33 (97.1%) | 34 (100%) |
Black n (%) | 1 (1.92%) | 1 (2.94%) | 1 (2.94%) | 0 (0.00) |
BMII kg/m2 Mean (SD) | 27 (3) | 27 (4) | 28 (3) | 27 (3) |
Asthma Characteristics | ||||
Prebronchodilator FEV1 (L), Mean (SD) | 2.53 (0.74) | 2.54 (0.73) | 2.59 (0.72) | 2.55 (0.69) |
% patients meeting FEV1 reversibility criteriaa | 78.8% | 88.2% | 73.5% | 70.6% |
ACQ-5 score mean (SD) | 1.2 (0.7) | 1.2 (0.6) | 1.2 (0.6) | 1.2 (0.7) |
Asthma symptom score (SD) | 0.8 (0.5) | 08 (0.5) | 0.8 (0.5) | 0.8 (0.5) |
FENO ppb (SD) | 57 (45) | 60 (47) | 53 (34) | 57 (39) |